Telomir Pharmaceuticals, Inc.

As of June 5, 2025, the technical trend is bearish with moderate strength, driven by bearish signals from the MACD, KST, and moving averages, despite a bullish RSI, indicating a prevailing negative sentiment and underperformance compared to the S&P 500.

Telomir Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $55.36 million. Key metrics include a debt equity ratio of 0.40 and a return on equity of 1,653.27%.

As of Jun 18, Telomir Pharmaceuticals, Inc. has a market capitalization of 55.36 million, with net sales of 0.00 million and a net profit of -12.52 million over the last four quarters. The company's shareholder's funds are 0.64 million, and total assets are 1.32 million.